目的 研究补肺活血胶囊联合孟鲁司特钠片治疗慢性阻塞性肺疾病稳定期的临床疗效。方法 选取2017年12月—2018年12月西部战区空军医院收治的110例慢性阻塞性肺疾病稳定期患者作为研究对象，将所有患者采用随机数字表法分为对照组和治疗组，每组各55例。对照组患者口服孟鲁司特钠片，1片/次，1次/d；治疗组患者在对照组治疗的基础上口服补肺活血胶囊，4粒/次，3次/d。两组均连续治疗3个月。观察两组患者的临床疗效，同时比较两组治疗前后的肺功能指标和血清炎性因子水平。结果 治疗后，对照组和治疗组的总有效率分别为78.18%、94.55%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者第一秒用力呼气容积（FEV1）、最大呼气流量（PEF）和FEV1/FVC水平均显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组肺功能指标水平显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者C反应蛋白（CRP）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组炎症因子水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 补肺活血胶囊联合孟鲁司特钠片治疗慢性阻塞性肺疾病稳定期具有较好的临床疗效，能够改善患者肺功能，降低血清炎性因子水平，具有一定的临床推广应用价值。

Objective To study the therapeutic effect of Bufei Huoxue Capsules combined with Montelukast Sodium Tablets in treatment of chronic obstructive pulmonary disease in stable period. Methods Patients (110 cases) with chronic obstructive pulmonary disease in stable period in Air Force Hospital of Western War Zone from December 2017 to December 2018 were randomly divided into control and treatment groups, and each group had 55 cases. Patients in the control group were po administered with Montelukast Sodium Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Bufei Huoxue Capsules on the basis of control group, 4 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the pulmonary function indexes and serum inflammatory factor level in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.18% and 94.55%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of FEV1, PEF, and FEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the pulmonary function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of CRP, IL-6, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the serum inflammatory factor level in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Bufei Huoxue Capsules combined with Montelukast Sodium Tablets has good clinical efficacy in treatment of chronic obstructive pulmonary disease in stable period, can improve the pulmonary function of patients, and reduce the level of serum inflammatory factors, which has a certain clinical application value.